Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus DEXASPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus DEXASPORIN.
ADVAIR DISKUS 500/50 vs DEXASPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP, leading to bronchodilation. Fluticasone propionate is a corticosteroid with anti-inflammatory activity, inhibiting inflammatory cell infiltration and mediator release.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
ADVAIR DISKUS 500/50: One inhalation (fluticasone propionate 500 mcg and salmeterol 50 mcg) twice daily (approximately 12 hours apart).
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
None Documented
None Documented
Fluticasone propionate: terminal elimination half-life is approximately 7.8 hours. Salmeterol: terminal elimination half-life is approximately 5.5 hours. Clinically, the half-life supports twice-daily dosing for sustained bronchodilation and anti-inflammatory effects.
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Fluticasone propionate: primarily hepatic (cytochrome P450 3A4) metabolism; renal excretion accounts for <5% as unchanged drug; fecal excretion accounts for the majority as metabolites. Salmeterol: primarily hepatic metabolism; renal excretion accounts for approximately 25% of the dose; fecal excretion accounts for approximately 60%.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid/Antibiotic Combination